论文部分内容阅读
目的 探讨非清除性异基因骨髓移植 (allo BMT)后供者淋巴细胞输注 (DLI)是否能减少移植相关并发症、相关死亡和减轻移植物抗宿主病 (GVHD) ,是否能增强移植物抗白血病 (GVL)效应。方法 荷L6 15白血病的 6 15 (H 2 k)小鼠 ,于接种白血病细胞后第 3天接受60 Coγ射线全身照射 (TBI,5Gy) ,照射当天移植供鼠BALB/c(H 2 d)小鼠的骨髓细胞 (3× 10 7)和脾细胞 (1× 10 7) ,移植后第 2天腹腔注射环磷酰胺 (2 0 0mg/kg) ,分别于移植后第 14天和第 2 1天输注供鼠脾细胞 (2× 10 7)或移植后第 14天输注经氢化可的松 (HC)和环孢菌素A(CsA)处理后的供鼠脾细胞 (5× 10 7) ,观察其抗白血病作用。结果 移植后第 2 1天输注供鼠淋巴细胞组和移植后 14天输注经HC、CsA处理后的淋巴细胞组小鼠生存期明显延长 ,分别为 (4 5 .1± 12 .8)d和 >5 0d ,而非清除性allo BMT组为 (2 6 .2± 3.6 )d ,第 14天输注供鼠淋巴细胞组为 (2 9.3± 3.7)d ,差异有显著性 (P <0 .0 1) ,且无明显GVHD发生。结论 非清除性allo BMT后早期输注经HC和CsA处理的供者淋巴细胞或延迟加用DLI可在减轻移植相关并发症的基础上 ,增强GVL效应 ,提高长期无病生存率
Objective To investigate whether donor lymphocyte infusion (DLI) after nonalcoholic allogeneic bone marrow transplantation (AML) can reduce graft-related complications, related death, and reduce graft-versus-host disease (GVHD), and whether it can enhance graft resistance. Leukemia (GVL) effect. METHODS: 6 15 (H 2 k) mice bearing L6 15 leukemia were irradiated with 60 Co γ-rays (TBI, 5 Gy) on day 3 after inoculation of leukemia cells. BALB/c (H 2 d) mice were transplanted on the day of irradiation. Rat bone marrow cells (3×10 7) and spleen cells (1×10 7) were intraperitoneally injected with cyclophosphamide (200 mg/kg) on the second day after transplantation on the 14th and the 2nd day after transplantation. Infusion of donor spleen cells (2 × 10 7) or 14 days after transplantation infusion of donor spleen cells after treatment with hydrocortisone (HC) and cyclosporin A (CsA) (5 × 10 7) Observe its anti-leukemia effect. Results The survival period of the lymphocyte group treated with HC and CsA was significantly prolonged on the first and second day after transplantation (14.11±12.8). d and >50 days, but not scavenging allo BMT group (2 6.2 ± 3.6) d, the donor lymphocyte group was (2 9.3 ± 3.7) d on the 14th day, the difference was significant (P < 0 .0 1) and no significant GVHD occurred. Conclusion The early infusion of donor lymphocytes treated with HC and CsA or delayed addition of DLI after nonalcoholic allo BMT can reduce GV effects and increase long-term disease-free survival on the basis of alleviation of transplant-related complications.